爱茉莉太平洋中国相关负责人对本报记者表示，集团不断加大投入培育品牌，基于消费习惯演变与市场 趋势的前瞻性布局，旨在通过渠道优化与数字化革新，更精准、高效地服务中国消费者。未来，雪花秀 将继续深化在华战略布局。 根据欧睿国际数据，2019—2024年间，雪花秀在中国护肤市场的份额自2021年触顶后已连续三年下滑， 规模较峰值几乎腰斩。 雪花秀近期被传预计在中国市场撤柜约30家，且主要集中在二线城市，长沙仅剩一家门店，南宁、苏州 等城市已无门店。 对于"雪花秀退出中国"的质疑，爱茉莉太平洋中国相关负责人12月11日回应《华夏时报》记者时予以否 认，并强调中国始终是雪花秀品牌重要的战略市场。 不过这依然折射出韩妆过往的光环已然黯淡，包括雪花秀在内的高端韩妆，在中国消费者心中的地位悄 然沉降。曾风靡一时的"韩妆滤镜"，其完美无瑕的水光肌与鲜明色调，正从年轻一代的审美与购物车中 渐渐淡出。这背后或许不仅是单品的失效，更是一种文化叙事与审美话语权的整体性转移。 撤柜，收缩 据天眼查，雪花秀（Sulwhasoo）是韩国高端草本护肤品牌，以人参为核心成分，是韩国爱茉莉太平洋 集团旗下三大高端品牌（爱茉莉太平洋、雪花秀、赫妍） ...

Core Insights - Amorepacific is introducing new brands to enhance its presence in the Chinese market, particularly in response to the declining momentum of its existing brands like Innisfree and Etude House [1] - The company has launched its skincare brand AESTURA, targeting the sensitive skin segment, with a primary focus on online sales in China [1] - The sensitive skin care market in China is experiencing significant growth, with a projected market capacity exceeding 30 billion yuan by 2024 [3] Company Developments - Amorepacific reported a consolidated sales revenue of 1.16 trillion KRW in its recent quarterly report, marking a 15.7% year-on-year increase, with overseas sales growing by 40.5% to 473 billion KRW [3] - The company appointed Taeho Park as the new president of Amorepacific China in April 2024, who has over 24 years of experience within the group [3] - Under Park's leadership, Amorepacific has implemented new market strategies, including the introduction of the high-end skincare brand AP in Shanghai [3] Industry Context - Other international beauty brands are expanding their market share, while Amorepacific's established brands lack appeal to younger consumers in China [4] - Industry experts suggest that introducing new brands is a preferred strategy for companies to attract the new generation of consumers in the competitive Chinese market [4]

Core Viewpoint - The article discusses the decline of Korean cosmetics in the Chinese market and their resurgence in the U.S. market, highlighting the factors contributing to these trends. Group 1: Decline in Chinese Market - Korean cosmetics, once popular in China due to hit dramas and celebrity endorsements, have seen a significant decline, with Amorepacific reporting a 30% year-on-year drop in sales in the Greater China region [1] - In 2021, China accounted for 53% of Korea's cosmetics exports, but this figure is projected to drop to around 25% by 2024, with the U.S. market showing the largest growth, nearing 20% of total exports [1] Group 2: Resurgence in U.S. Market - Korean cosmetics are making a comeback in the U.S. market, aided by the popularity of the 10-step skincare routine and the influence of social media platforms like TikTok and Instagram [2][6] - Amorepacific has initiated brand revitalization efforts, including rebranding its high-end skincare line Sulwhasoo and hiring well-known celebrities as brand ambassadors, leading to double-digit sales growth for brands like Laneige [3][5] - The introduction of a wider range of product shades to cater to diverse skin tones has significantly boosted sales, as seen with the brand Tirtir, which expanded from 3 to 40 shades [5] Group 3: Market Dynamics and Consumer Behavior - The influence of K-culture, including K-dramas and K-pop, continues to drive consumer interest in Korean cosmetics in the U.S. market [7] - The absence of tariffs on most Korean cosmetics due to the U.S.-Korea Free Trade Agreement has made these products more competitively priced compared to local brands [7] - The "lipstick effect" suggests that consumers are more willing to try affordable and innovative Korean cosmetics during economic downturns [7] Group 4: Distribution and Marketing Strategies - Korean brands are increasingly focusing on offline retail experiences, signing long-term leases in key locations to attract local consumers [8] - Initiatives like the opening of Olive Young stores in the U.S. aim to enhance consumer exposure to Korean beauty products [10] Group 5: Challenges Ahead - Korean cosmetics companies face challenges such as stricter U.S. FDA regulations and potential tariff impacts due to changing political climates [11]